MTOR and cervical cancer: The most significant tumor reduction of −65%, with the response still ongoing for more than a year after the data cut-off, was observed in a cervical cancer patient with ErbB2 overexpression and additional PIK3CA, AKT, and mTOR mutations (Figure 2).